Insights

Access our latest insights & resources

Filters
Lowry Special Report From Unloved to Exuberant: Medium-Term Momentum Reversals

Lowry Special Report From Unloved to Exuberant: Medium-Term Momentum Reversals

Research, Technical
Media commentators use "market momentum" to describe the enthusiasm...
Read more
Lowry Weekly ETF Commentary – January 05, 2024

Lowry Weekly ETF Commentary – January 05, 2024

Research, Technical
Despite the stock market's turbulent beginning to the new year, some...
Read more
See behind the curtain with CFRA’s custom forensic due diligence

See behind the curtain with CFRA’s custom forensic due diligence

Case Study, Forensic
CFRA found several inconsistencies in the data reported in...
Read more
Lowry Weekly Sector Commentary- January 03, 2024

Lowry Weekly Sector Commentary- January 03, 2024

Research, Technical
Lowry's core indicators now support a healthier investing environment.
Read more
2024 Technology Hardware/Storage Outlook

2024 Technology Hardware/Storage Outlook

Fundamental, Research
The technology hardware industry has faced numerous challenges in the...
Read more
Drug Distributors: Prescription Volumes, New Therapies Powering Higher Stock Prices

Drug Distributors: Prescription Volumes, New Therapies Powering Higher Stock Prices

Fundamental, Research
Drug distributors MCK, COR, and CAH have been performing significantly...
Read more
ETF Trends to Watch in 2024: Part 2

ETF Trends to Watch in 2024: Part 2

Other, Research
As the U.S. ETF industry crosses the $8 trillion asset threshold to...
Read more
European Maritime Logistics: Overcapacity and Subdued Demand Sink Freight Rates

European Maritime Logistics: Overcapacity and Subdued Demand Sink Freight Rates

Fundamental, Research
Maritime logistics are grappling with a new reality characterized by plummeting market freight...
Read more
Consumer Staples: Risks From Anti-Obesity Medications Likely Overblown

Consumer Staples: Risks From Anti-Obesity Medications Likely Overblown

Fundamental, Research
Anti-obesity medications (AOMs), including glucagon-like peptide-1 (GLP-1) agonists...
Read more
Amazon: $7+ EPS by 2025 Could Be the Next Catalyst

Amazon: $7+ EPS by 2025 Could Be the Next Catalyst

Fundamental, Research
Wall Street has historically valued AMZN shares using nontraditional relative valuation metrics.
Read more